Publication | Closed Access

166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study

Breast OncologyInitial ResultsMedicineCancer Cell BiologyPathologyImmune Checkpoint InhibitorBreast CancerMolecular OncologyPhase Ib/ii StudyCancer TreatmentBreast SurgeryOncologyRadiation OncologyCancer Research